Climb Bio Inc. Common Stock (CLYM)
Stock · NASDAQ · Health Care
$9.82as of 10/16/2026
Price chart
Active signals
CLYM Signal Track Record
How signals performed across all stocks →What CLYM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +1.5% | 58% | September 18, 2026 |
| Bollinger Band Breakout | 23 | +5.0% | 57% | August 13, 2026 |
| Bollinger Band Breakdown | 20 | +4.7% | 70% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -3.9% | 33% | October 11, 2024 |
| Any 20-session window (baseline) | -1.1% | 47% |
Computed by MarketWall from daily closing prices since May 24, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 28
- Website
- climbbio.com/
Fundamentals
- 1-day range
- $10.25$10.94
- Market cap
- $801.68M
- P/E (trailing)
- —
- P/E (forward)
- -10.74
- EPS (trailing)
- $-0.82
- Dividend yield
- —
- Beta
- -0.01
- Avg. volume
- 1.36M
Forecasts
14 analyst ratings
Climb Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CLYMClimb Bio Inc. Common Stock$9.82▼ 9.99%Market cap $801.68MP/E —$1.64$18.33
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
- DRUGBright Minds Biosciences Inc. Common Stock$51.3▼ 5.37%Market cap $792.81MP/E —$68.02$170
- KURAKura Oncology Inc. Common Stock$9.08▼ 6.39%Market cap $823.83MP/E —$7.36$13.9
- PHARPharming Group N.V. ADS each representing 10 ordinary shares$9.36▼ 2.80%Market cap $766.28MP/E 73.41$0.8338$1.82
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
- DSGNDesign Therapeutics Inc. Common Stock$10.31▼ 1.62%Market cap $861.75MP/E —$5.28$17.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CLYM Climb Bio Inc. Common Stock | $801.68M | — | $9.82 | ▼ 9.99% | $1.64$18.33 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
| DRUG Bright Minds Biosciences Inc. Common Stock | $792.81M | — | $51.3 | ▼ 5.37% | $68.02$170 |
| KURA Kura Oncology Inc. Common Stock | $823.83M | — | $9.08 | ▼ 6.39% | $7.36$13.9 |
| PHAR Pharming Group N.V. ADS each representing 10 ordinary shares | $766.28M | 73.41 | $9.36 | ▼ 2.80% | $0.8338$1.82 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
| DSGN Design Therapeutics Inc. Common Stock | $861.75M | — | $10.31 | ▼ 1.62% | $5.28$17.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing IntervalSeekingAlpha · 10/7/2026
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and BudoprutugYahoo · 10/2/2026
- Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026Benzinga · 10/2/2026
- Raymond James Updates Healthcare Top Picks for OctoberYahoo · 10/1/2026
- The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' DataYahoo · 9/23/2026
Insider Activity
Insider Actions →- Stephen Basil Thomas · September 15, 2026 · Sale100.0K @ $13.67
- Celebi Breanna Maurine · June 29, 2026 · Grant70.3K
- RA CAPITAL MANAGEMENT, L.P. · June 29, 2026 · Grant70.3K
- RA Capital Healthcare Fund LP · June 5, 2026 · Grant40.0K
- Levin Andrew David · June 5, 2026 · Grant40.0K
- Stephen Basil Thomas · June 5, 2026 · Grant40.0K
- Dunn Judith · June 5, 2026 · Grant40.0K
- Cumbo Alexander · June 5, 2026 · Grant40.0K
- Kimberlee C. Drapkin · June 5, 2026 · Grant40.0K
- WILLIAMS DOUGLAS E · June 5, 2026 · Grant40.0K
- RA Capital Healthcare Fund LP · April 29, 2026 · Grant2.11M @ $9.5
Institutional Ownership
March 31, 2026
- Total shares held
- 32.21M
- Total value held
- $207.23M
- Institutional holders
- 77
- Unknown11.30M
- Unknown2.59M
- Unknown1.92M
- Unknown1.53M
- Unknown1.33M
- Unknown1.28M
- Unknown1.18M
- Unknown1.00M
- Unknown773.1K
- Unknown700.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets
Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.